Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya.
about
Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoniCirculating antigen tests and urine reagent strips for diagnosis of active schistosomiasis in endemic areasReview: analysis of parasite and other skewed countsReduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoniUtility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic reviewApplication of RNAi to Genomic Drug Target Validation in SchistosomesNon-invasive sampling of schistosomes from humans requires correcting for family structure.Evaluation of urine CCA assays for detection of Schistosoma mansoni infection in Western Kenya.Applying evolutionary genetics to schistosome epidemiology.Genetic structure of Schstosoma mansoni in western Kenya: the effects of geography and host sharing.Mefloquine, a new type of compound against schistosomes and other helminthes in experimental studies.Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approachAdvances in the Diagnosis of Human Schistosomiasis.Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt.Repeated Schistosoma japonicum infection following treatment in two cohorts: evidence for host susceptibility to helminthiasis?Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor ImatinibEfficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regionsOf monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates.New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel.Effect of school based treatment on the prevalence of schistosomiasis in endemic area in yemen.Longitudinal analysis of antigen specific response in individuals with Schistosoma mansoni infection in an endemic area of Minas Gerais, Brazil.Assessment of quality of life as a tool for measuring morbidity due to Schistosoma mansoni infection and the impact of treatment.Schistosoma mansoni reinfection: Analysis of risk factors by classification and regression tree (CART) modeling.Sonographic response in the liver and urinary bladder of children 14 months after treatment for schistosomiasis.The Efficacy of Single-Dose versus Double-Dose Praziquantel Treatments on Schistosoma mansoni Infections: Its Implication on Undernutrition and Anaemia among Primary Schoolchildren in Two On-Shore Communities, Northwestern Tanzania.Effect of ozonide OZ418 against Schistosoma japonicum harbored in mice.Effectiveness of synthetic trioxolane OZ78 against Schistosoma japonicum in mice and rabbits.Schistosomiasis and its treatment.Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: a scoping review of experimental studies.The effects of subcurative praziquantel treatment on life-history traits and trade-offs in drug-resistant Schistosoma mansoni.
P2860
Q21092289-0AE49A86-7C4B-46F1-BCE5-3A8C850C4EF2Q24187049-A54EDCC3-F001-4D0C-B293-5CE4462B76DEQ26864243-8D6806B3-7959-4BD8-801D-B7DD82CFDEC9Q28475935-F474286A-4180-4ACE-8C86-D28DA1267B77Q28477145-C5163BF2-D596-406E-8039-F05FC76568CAQ28547348-B2E7CA31-04E4-418D-84A7-82749A6ECEB2Q31140183-5C9E1886-207D-4343-BE29-B7BCDFC6A50FQ33808771-CE83A493-6D09-4E3A-8678-0E3488BA62BFQ33820116-DD7A356F-6D82-4584-B50A-B3EB0C68A165Q33941750-F860BAF6-F1E9-4B33-83F9-336B3383DD43Q34366867-FF7CFEDE-4016-4AEF-B8B8-FE1591BF4281Q34461420-ABCD4911-91EC-4C0B-943A-632E75F5CB34Q34487530-C766899F-C584-4711-96FF-6C1514D04EF8Q34496255-579AB47B-D153-465F-81CC-F44D0C7EA7F3Q34626126-E6619F46-D543-4C1A-8ABD-806AE04DCCDBQ34705820-715213A0-C3CD-4A9E-9F09-29BFE853B6DFQ35272747-E30ADE5D-33CA-4D22-8411-CD526D9F7E2AQ35569944-97CECFB1-AE96-4AC4-B4C4-D4E6C57E988DQ35905176-59EC6CB5-FF71-453E-8C25-0FE77A3DFF4EQ37046862-D6AA1FD8-93C8-4203-A34F-C6ACD06DA615Q37464180-EBB9812C-88D4-4133-98BA-67CB9122F269Q37572986-D6224484-D228-4E8E-9D7D-3C1606FCD862Q39019358-D79A3ACA-BFA5-4F51-87D3-0E439B91461BQ43804277-7EEA620A-D3A7-4D19-A3D2-6344CF247A74Q43924119-756BE1C6-DEC8-4602-AA7C-CFF07FDC2BA8Q47872179-18FD6945-2409-4AF7-8574-F0EE42A9609AQ47998506-F2E947EE-8521-40FC-B87C-472BF4C162BEQ48478678-A85BD1E8-6067-4DC1-B28C-C3811251550BQ49632990-EA584AA4-7624-4A8B-A6DC-7F527566880EQ52325706-FA316AF9-EBFA-4DB5-B17A-D2C1E8E6C58D
P2860
Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Impact of intense, longitudina ...... posed adults in western Kenya.
@ast
Impact of intense, longitudina ...... posed adults in western Kenya.
@en
Impact of intense, longitudina ...... posed adults in western Kenya.
@nl
type
label
Impact of intense, longitudina ...... posed adults in western Kenya.
@ast
Impact of intense, longitudina ...... posed adults in western Kenya.
@en
Impact of intense, longitudina ...... posed adults in western Kenya.
@nl
prefLabel
Impact of intense, longitudina ...... posed adults in western Kenya.
@ast
Impact of intense, longitudina ...... posed adults in western Kenya.
@en
Impact of intense, longitudina ...... posed adults in western Kenya.
@nl
P2093
P2860
P921
P1476
Impact of intense, longitudina ...... posed adults in western Kenya.
@en
P2093
Carla L Black
Daniel G Colley
Diana M S Karanja
Michelle L Steinauer
Pauline N M Mwinzi
W Evan Secor
P2860
P304
P356
10.1111/J.1365-3156.2009.02234.X
P5008
P577
2009-02-14T00:00:00Z